...
首页> 外文期刊>Journal of mental health >Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD).
【24h】

Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD).

机译:拉莫三嗪增强抗药性单相抑郁症(TRD)的系统评价。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVE: Our aim was to review all the evidence of lamotrigine's effectiveness in treatment resistant depression after at least one failed antidepressant trial. METHOD: We used a systematic search strategy to identify studies that included adults aged 18-65 years with a diagnosis of unipolar depression who had not responded to at least a 4-week course of a recommended dose of an antidepressant. RESULTS: We found only one randomized, double blind study that has been published, showing its effectiveness for treatment-resistant depression. In this study, lamotrigine was found statistically superior to placebo on the CGI scale for severity and improvement; however, it was not on the HAM-D (primary end point) and MADRS scales. There were a number of smaller non RCT's which are included. CONCLUSIONS: There is little evidence to guide the use of lamotrigine for depression that has not responded to a course of antidepressants. Treatment-refractory depression continues to be significant mental health problem and large RCT trials are needed to inform clinical practice.
机译:目的:我们的目的是在至少一项抗抑郁药试验失败后,复查拉莫三嗪治疗抗抑郁药的有效性的所有证据。方法:我们使用系统的搜索策略来确定研究对象,包括诊断为单相抑郁症的18-65岁成年人,他们对推荐剂量的抗抑郁药至少持续4周疗程没有反应。结果:我们发现只有一项随机,双盲研究已发表,显示了其对难治性抑郁症的有效性。在这项研究中,拉莫三嗪在严重程度和改善方面在统计学上优于CGI量的安慰剂。但是,它不在HAM-D(主要终点)和MADRS量表上。其中包括许多较小的非RCT。结论:几乎没有证据指导拉莫三嗪用于对抗抑郁药疗程没有反应的抑郁症。难治性抑郁症仍然是重要的心理健康问题,需要大量的RCT试验来指导临床实践。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号